This webinar provides an in-depth exploration of HER2-positive breast cancer, covering both the pathological and molecular dimensions of the disease. Attendees will gain expert perspectives on the latest developments in tumour biology, molecular profiling, and diagnostic techniques, as well as their influence on clinical decision-making and patient management. The session aims to deliver a clear and current understanding of HER2-positive breast cancer, emphasizing how advances in research and pathology contribute to more personalized treatment strategies.

• 18:00-18:05 | Welcome and introduction – Aleksandra Filipovic, UK
• 18:05-18:25 | HER2 positive breast cancer. The pathological perspective – Esther Sanfeliu, ES
• 18:25-18:45 | HER2 positive breast cancer. Molecular perspective – Mattia Rediti, IT
• 18:45-18:55 | Discussion and Q&A
• 18:55-19:00 | Closure – Aleksandra Filipovic, UK

Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.

Views and opinions expressed are however, those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

You can find more posts featuring SPCC on OncoDaily.